Biologics that were introduced in the mid-1990s to treat Crohn disease haven’t had the hoped-for effect of reducing remissions or hospitalizations, according to a new study. But the investigators suggested that the drugs might have reduced Crohn severity for many patients, leading to a decrease in small bowel resections from 2003 to 2013.
The investigators analyzed Crohn disease hospitalizations using data from the National Inpatient Sample of the Healthcare Cost and Utilization Project. They found no change in hospitalizations with Crohn as the primary diagnosis during the study period. But the number of hospitalizations with the condition listed as a contributing factor increased from 120 209 in 2003 to 196 480 in 2013.
Effect of Crohn Disease Biologics. JAMA. 2017;317(20):2055. doi:10.1001/jama.2017.5897
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: